MARY ANN GRAY
CIK 1261974 · last filed 2026-06-05
MARY ANN GRAY is a corporate insider who has filed 94 SEC Form 4 insider transactions across 15 companies since 2007. The most recent filing, for KROS, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$829.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.95M
15
94
-$829.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 12,392 | $10.07 | $124.8K | $0 | 7 | 2026-06-05 |
| RAPT Therapeutics, Inc. (RAPT) Delisted | Director | 4,956 | $58.01 | $287.5K | $0 | 14 | 2026-02-02 |
| CMPX | Director | — | $2.04 | — | $0 | 5 | 2026-01-05 |
| BCAB | Director | 1,548 | $3.53 | $5.5K | $0 | 9 | 2025-06-18 |
| PALI | Director | — | $2.02 | — | $0 | 3 | 2023-11-24 |
| SRPT | Director | 12,356 | $15.43 | $190.7K | $0 | 8 | 2022-03-08 |
| PALISADE BIO, INC. (SNCA) Delisted | Director | — | $9.96 | — | $0 | 2 | 2021-04-26 |
| SENOMYX INC (SNMX) Delisted | Director | 0 | — | — | $10.0K | 10 | 2018-11-02 |
| JUNIPER PHARMACEUTICALS INC (JNP) Delisted | Director | 0 | — | — | $0 | 4 | 2018-08-15 |
| SELLAS Life Sciences Group, Inc. (GALE) Delisted | Director | 1,306 | — | — | $0 | 6 | 2017-10-10 |
| ACAD | Director | 139,476 | $26.01 | $3.63M | -$847.8K | 13 | 2016-06-09 |
| DYAX CORP (DYAX) Delisted | Director | 0 | — | — | $0 | 5 | 2016-01-22 |
| TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | Director | — | — | — | $0 | 2 | 2015-01-30 |
| GTC BIOTHERAPEUTICS INC (GTCB) Delisted | Director | 1,100 | — | — | $8.8K | 3 | 2008-06-25 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (TELK) Delisted | Director | — | — | — | $0 | 2 | 2008-05-22 |
Recent Filings
94 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | KROS | Grant (A) | +7,142 | $0 | EDGAR |
| 2026-03-05 | — | Mixed | −4,956 | $0 | |
| 2026-02-02 | RAPT Therapeutics, Inc. (RAPT) Delisted | Grant (A) | +4,956 | $0 | EDGAR |
| 2026-01-05 | CMPX | Grant (A) | — | $0 | EDGAR |
| 2025-06-18 | BCAB | Grant (A) | +23,500 | $0 | EDGAR |
| 2025-06-06 | KROS | Grant (A) | +5,250 | $0 | EDGAR |
| 2025-06-02 | RAPT Therapeutics, Inc. (RAPT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-04-02 | RAPT Therapeutics, Inc. (RAPT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-13 | CMPX | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | BCAB | Grant (A) | +16,500 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.